Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SLO-PHYLLIN vs ACCURBRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SLO-PHYLLIN (theophylline) is a xanthine bronchodilator that relaxes bronchial smooth muscle, likely by inhibiting phosphodiesterase, increasing intracellular c AMP, blocking adenosine receptors, and enhancing endogenous catecholamine release.
Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., COPD, emphysema, chronic bronchitis),Off-label: Apnea of prematurity,Off-label: Adjunctive therapy in acute asthma exacerbations (rarely used)
FDA-approved: Treatment of COPD exacerbations,Off-label: Acute asthma exacerbations
Theophylline (Slo-Phyllin) immediate-release: 100-200 mg orally every 6 hours; sustained-release: 200-400 mg orally every 12 hours. Dose titrated to serum theophylline concentration of 5-15 mcg/m L.
Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.
Terminal elimination half-life is approximately 3-8 hours in adults (non-smokers, healthy), 1-5 hours in smokers, and 20-30 hours in neonates. Clinical context: Half-life is prolonged in hepatic cirrhosis, heart failure, and with certain drug interactions (e.g., cimetidine, ciprofloxacin).
Terminal elimination half-life: 8-12 hours (healthy adults), prolonged to 15-20 hours in hepatic impairment. Clinical context: Supports twice-daily dosing in most patients.
Primarily hepatic via CYP450 enzymes: CYP1A2, CYP2E1, CYP3A4; metabolite: 1,3-dimethyluric acid. Approximately 10% excreted unchanged in urine.
Ipratropium: minimally metabolized via hydrolysis and conjugation; Albuterol: primarily metabolized by catechol-O-methyltransferase (COMT) and sulfation.
Renal: ~10% unchanged; hepatic metabolism accounts for ~90% of elimination, with metabolites excreted in urine. Fecal: <5%.
Renal: 60-70% as unchanged drug; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
Approximately 40% bound to albumin; binding is saturable and decreased in neonates, hepatic disease, and acidosis.
85-90% bound to albumin.
0.45 L/kg (range 0.3-0.7 L/kg). Clinical meaning: Distributes evenly into body water and highly perfused tissues; Vd increased in premature infants and decreased in obesity.
0.8-1.2 L/kg (wide distribution into tissues, including lungs).
Oral immediate-release: 96-100%; oral sustained-release (Slo-Phyllin): 90-100% relative to immediate-release; rectal: variable (~80-100% for enema); IV: 100%.
Oral: 60-80% (first-pass metabolism reduces bioavailability).
No specific dose adjustment is required for renal impairment. However, monitoring serum concentrations is recommended due to altered clearance in severe renal failure (GFR <10 m L/min).
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing oral dose by 50% or extending interval due to accumulation of acetylcysteine metabolites.
Child-Pugh Class B or C: Reduce dose by 50% and monitor serum concentrations closely. Avoid use in severe hepatic impairment if possible.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential increased exposure.
Starting dose: 5 mg/kg/day orally in divided doses every 6 hours (immediate-release) or every 12 hours (sustained-release). Titrate based on serum concentrations, targeting 5-15 mcg/m L. Maximum dose: 24 mg/kg/day or 900 mg/day, whichever is less.
Inhalation: Infants and children: 1-2 m L of 20% solution or 2-4 m L of 10% solution nebulized three to four times daily. Oral: Not typically recommended for chronic use; for acetaminophen overdose, weight-based dosing is used.
Start at low end of dosing range (e.g., 200-300 mg/day sustained-release). Monitor serum concentrations carefully as clearance is reduced in elderly patients, increasing risk of toxicity.
No specific dose adjustment; monitor for adverse effects such as bronchospasm or nausea. Use with caution in elderly with renal impairment (refer to renal adjustment).
No FDA boxed warning.
No FDA boxed warning exists for this combination product.
Concurrent illness (fever, influenza), hepatic impairment, elderly, and smoking alter metabolism; narrow therapeutic index (10-20 mcg/m L); monitor serum levels; risk of seizures, arrhythmias, and death with toxicity; reduce dose with CYP1A2 inhibitors (cimetidine, fluoroquinolones, macrolides) or inducers (smoking, rifampin, phenytoin); caution in peptic ulcer disease, seizure disorders, cardiac arrhythmias.
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension), worsening of narrow-angle glaucoma, urinary retention, hypokalemia, and immediate hypersensitivity reactions.
Hypersensitivity to theophylline or any component,Pre-existing arrhythmia (especially tachyarrhythmias),Active seizure disorder not adequately controlled
Hypersensitivity to ipratropium, albuterol, or atropine; history of anaphylaxis to soya lecithin or related food products; narrow-angle glaucoma; prostatic hyperplasia or bladder neck obstruction (relative).
Avoid high-fat meals as they may alter absorption of sustained-release preparations. Limit caffeine-containing foods and beverages. Avoid charcoal-broiled foods, which can increase metabolism.
High-fat meals can increase absorption of theophylline; take on an empty stomach or with light snack for consistent effect. Avoid large amounts of charcoal-broiled foods as they may decrease drug levels. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) can potentiate side effects such as nervousness, tremor, and insomnia. Charbroiled meats and cruciferous vegetables (broccoli, Brussels sprouts) may induce metabolism and reduce effectiveness. Grapefruit juice may increase theophylline levels; avoid concurrent use.
Theophylline (Slo-Phyllin) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects at high doses, but human data are limited. First trimester exposure is not associated with major congenital malformations. Third trimester use may lead to transient neonatal apnea, jitteriness, or tachycardia due to placental transfer. No increased risk of preterm birth or low birth weight has been consistently demonstrated.
No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach therapeutic concentrations if maternal doses are high. Breastfeeding is generally considered compatible, but monitor the infant for signs of theophylline toxicity (e.g., irritability, insomnia, tachycardia).
Not known if excreted in human breast milk. Caution advised; consider developmental benefits vs risks. M/P ratio not available.
Pregnancy may decrease theophylline clearance by 20-30%, particularly in the third trimester, due to reduced hepatic metabolism. Dose adjustments may be needed to maintain therapeutic levels. Postpartum, clearance returns to prepregnancy levels within 4-6 weeks; reduce dose accordingly to avoid toxicity.
No dose adjustment routinely recommended; however, increased clearance may require monitoring for therapeutic effect.
Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Adjust dose in patients with heart failure, liver disease, or on CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine). Do not crush or chew sustained-release tablets. Cigarette smoking induces metabolism, requiring higher doses.
Accurbron (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L. Hepatic metabolism is highly variable; monitor levels closely in patients with liver impairment, heart failure, or those on interacting drugs. Smoking induces metabolism, requiring higher doses. Use with caution in elderly and patients with seizure disorders or peptic ulcer disease. Do not crush or chew extended-release tablets.
Take this medication exactly as prescribed, usually every 8-12 hours.,Do not crush or chew the tablets; swallow them whole.,Avoid excessive caffeine intake (coffee, tea, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, or irregular heartbeat.,Do not change brands or formulations without consulting your doctor.
Take exactly as prescribed; do not change dose without doctor approval.,Do not crush or chew sustained-release tablets.,Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report any symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, seizures.,Smoking or quitting smoking can affect theophylline levels; inform your doctor about any changes in smoking habits.,Keep regular appointments for blood tests to monitor drug levels.,Avoid taking other medications, including over-the-counter drugs and herbal supplements, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SLO-PHYLLIN vs ACCURBRON, answered by our medical review team.
SLO-PHYLLIN is a Xanthine Bronchodilator that works by SLO-PHYLLIN (theophylline) is a xanthine bronchodilator that relaxes bronchial smooth muscle, likely by inhibiting phosphodiesterase, increasing intracellular c AMP, blocking adenosine receptors, and enhancing endogenous catecholamine release.. ACCURBRON is a Methylxanthine Bronchodilator that works by Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SLO-PHYLLIN and ACCURBRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SLO-PHYLLIN is: Theophylline (Slo-Phyllin) immediate-release: 100-200 mg orally every 6 hours; sustained-release: 200-400 mg orally every 12 hours. Dose titrated to serum theophylline concentration of 5-15 mcg/m L.. The standard adult dose of ACCURBRON is: Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SLO-PHYLLIN and ACCURBRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SLO-PHYLLIN is classified as Category C. Theophylline (Slo-Phyllin) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects at high doses, but human data are limited. First trimester expos. ACCURBRON is classified as Category C. No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.